Search

Your search keyword '"Shimose S"' showing total 205 results

Search Constraints

Start Over You searched for: Author "Shimose S" Remove constraint Author: "Shimose S"
205 results on '"Shimose S"'

Search Results

1. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

3. 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

4. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

5. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

6. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

7. 84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

9. Origami Medial Femoral Condyle Flap for Finger Joint Reconstruction

20. Interferon-α/β receptor as a prognostic marker in osteosarcoma.

21. 182P A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe.

27. 185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study.

28. Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas

29. Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas

30. Nerve tolerance to high-dose-rate brachytherapy in patients with soft tissue sarcoma: a retrospective study

32. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

33. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

34. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

36. 188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab.

37. 173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB).

38. 154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB).

40. Global multi-stakeholder endorsement of the MAFLD definition

41. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison

42. Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma.

43. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.

44. A Multidisciplinary Therapeutic Approach Proposal for Huge Hepatocellular Carcinomas Exceeding 10 cm in Diameter.

45. Japanese orthopaedic association (JOA) clinical practice guidelines on the management of malignant bone tumors - Secondary publication.

46. Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.

47. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

48. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

49. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.

50. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.

Catalog

Books, media, physical & digital resources